Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BPURQ: SEC Suspension and ADMIN Proceeding:
http://sec.gov/litigation/suspensions/2011/34-64879.pdf
http://sec.gov/litigation/suspensions/2011/34-64879-o.pdf
http://sec.gov/litigation/admin/2011/34-64880.pdf
ME to i had lots of bpurq at 0.02 sold most of it at 100 percent havent bought more yet but unwilling to sell what i have left. the blood replacement product is still being used by the military i think if it ever gets fda approvial it will be huge!!(somtimes i like them better with the q )vstnq bought for 0.02 sold for 0.30 and it still ran up to 2.0 go figure ybtvq bought in for a penny sold for 0.05 0.10 then bought back for 0.003 and sold for 0.02 before they canciled. with the q companys i like to start pounding them at 0.02 and play from there. dsupq i made money on all the way until they canciled bought some cemjq at 0.10 sold for 0.50 and it ran over 1.0 had some abwtq sold it at 100 percent gain becouse my learq shares canciled before i got my money off the board thought abwtq was next if you have any good q companys under 0.02 let me know also epix i got for a penny and sold for dime when they were scheduled for liquidation go figure. bankrupt is a better entry point than profits!!!!
Who dumped 300,000 shares at 0.006? Why? Will the shares be canceled
very soon? Today / tomorrow or Friday? I still own 1M+ cheap shares.
It is because someone bought over 6M cheap shares at 0.0041 ~ 0.006 and they want to push the price up to make huge profit or make even. Please do not sell your shares at the bid because 0.0041 is bottom!
WHY IS THIS pos MOVING ?
It is up 125%! Please do not sell your shares at the bid! Buy ASAP!
I am proud of over $20,000 profit now! 0.0041 must be the bottom...
This CH11 stock has 0.0041 ~ 0.005 per share liquidation value. That is why the big sellers refused to sell below 0.0041. But when will the shareholders receive the distribution from the liquidation?
"Buy Confirmed" by AmericanBull! Let's push the price up to 0.01 so
that I can sell 4M shares to you guys at 0.009 ~ 0.01 today. Please
do not sell at the bid and buy at the ask only ASAP...
Who are those very stupid sellers who sold the shares at the bottom?
So far only about 1M shares sold at 0.0041 which is unbreakable...
Sell....Buy....Sell...Buy.......Would laugh at this one but I made a bunch with another Q recently....but that was a completely different animal!!
i thought you said to sell it!! hahahaa!!
BPURQ is finally bottomed out at 0.0041 today! I am glad to own near 4M cheap shares which I bought at 0.0041 ~ 0.006. I bet next week it will rally to 0.01 ~ 0.0123. Only about 1M shares sold at 0.0041...
By the way who were those very stupid sellers which sold 6M+ shares
at 0.0041 ~ 0.006. They must kick themselves while they see 0.01x...
New 52-week low .0041 was created today! Sell at the bid ASAP before
the CH11 trash hits another new low 0.003 or even 0.002... No value!
New 52-week low .0051 was created today! Sell at the bid ASAP before
the CH11 trash hits another new low 0.004 or even 0.003...
New 52-week low 0.0071 was created today! Sell the pos scam at the bid ASAP before it hits another new low 0.004 or even 0.003...
Who are those very stupid sellers which sold the shares at 0.008 ~
0.01 yesterday and today? The stock is already bottomed out at 0.008
and rally to 0.0125! Anyway I hold my millions of cheap shares now.
It is strong up 57% today from 0.008 to 0.0125! Please do not sell your shares at the bid & buy the shares at the ask price only ASAP!
New 52-week low 0.008 was created today! Sell the pos scam at the bid ASAP before the very sick CEO cancels all the common shares...
"Sell Confirmed" by AmericanBull! I bet another new low 0.003 will be hit very soon. The OS is huge now. Dilution continues everyday...
Why the other people could sell the shares at 0.015 ~ 0.0195 but I
could not sell any share at those prices? I have near 1.5M shares to
sell at 0.015 ~ 0.0195. Does anyone want to buy my shares at 0.0165?
I am glad to see BPURQ was up strongly today! Hope I could sell out
my 1M plus cheap shares at 0.0158 ~ 0.0195 to make decent profits...
Please do not sell your shares at the bid and buy at ask only ASAP!
It is finally bottomed out at 0.011! I am happy with my 1M plus damn
cheap shares at 0.011 ~ 0.017 and will sell at 0.018 ~ 0.025 to make
big profits! Anyway who are those very stupid sellers which sold the
shares at 0.011 ~ 0.014? The OS is only about 40M shares. Buy ASAP!
New 52-week low 0.011 was created yesterday! Sell at the bid ASAP
before the very sick CEO cancels all the common shares. Soon 0.001!
You're welcome, hubstocker.
I've never had warrants either. Personally, I wouldn't hold them. I assume you already know the Q at the end of the symbol means they're in bankruptcy. The E means they were delinquent in SEC filings, specifically they failed to comply with NASD 6530.
Here are a few links to check out:
http://www.otcbb.com/asp/dailylist_detail.asp?d=10/19/2009
http://www.otcbb.com/news/2005/GeneralNews/threestrikes3.stm
http://www.craigmacauley.com/BiopurePleadings.html
I no longer have a position in Biopure. I was an investor since 2003 and sold a year ago. I lost a few grand, but I did get a securities litigation settlement check. It was almost 10% of my investment.
Never had warrants before and tried reading up on it. Just curious from your prospective, is it a good idea to hold them? Because what was interesting when I orginally purchased them they were in my account as BPUFQ for a few days I think then the changed stock ticker changed to BRUFE and I think after a week or so returned back to BPUFQ ticker.
BPURQ is Class A common stock and BPUFQ (as well as BPUAQ, BPUDQ, and BPUEQ) are warrants.
What is the difference between BPURQ and BPUFQ ticker?
I guess no value here huh ? Man, VI, you get around ! LOL
New 52-week low .015 was created today! Sell at the bid ASAP before
the pos scam hits another new low 0.01. The liquidation value must
be zero. That is why the sharp price decline today. No value left!
New 52-week low 0.019 was created today! It seems oversold now. Who
are selling the shares at such low prices? Why did not they sell at
0.04 ~ 0.045 before? Keep in mind there is a liquidation value left
during the CH11 process and it may worth 0.025 ~ 0.045 per share...
New 52-week low 0.02 was created today! 0.02 seems the bottom price
and the strong bounce will rally to 0.04 ~ 0.045 within this week.
Another new 52-week low 0.021 was created today! Smart sellers sold
their shares at 0.021 ~ 0.022 to avoid selling at 0.02 or below...
New 52-week low 0.022 was created yesterday! Smart sellers dumped their shares at 0.022 ~ 0.0249 to avoid selling at 0.02 ~ 0.021...
Smart sellers dumped near 100,000 shares at 0.025 yesterday! It is
much better than selling at 0.02 ~ 0.024 later. 0.045 is the roof!
Who are those very smart sellers which dumped the shares at 0.026? Otherwise they maybe end up selling at 0.02 ~ 0.025 once the bottom
0.025 is broken which is a sure thing. Sell at the bid price ASAP!
Who are those very smart sellers which sold the shares at 0.027? It
may test the bottom .025 today and break it down! Sell at the bid ASAP to avoid end up selling at 0.02 or even 0.01.
Who are those very smart sellers which sold the shares at 0.028? It
may test the support .027 today or even break down the bottom .025!
Sell at the bid ASAP if you not want to be end up selling at 0.02.
Who are those very stupid sellers which sold near 200,000 shares at 0.03 during the past three days? Today they may sell another 90,000
shares at 0.03 or even break down the support .03. Buy at ask ASAP!
Who are those very stupid sellers who sold tens of thousands shares
at 0.03 yesterday and today? BPURQ is already bottomed out at 0.027
even the 52-week low is 0.025 and it already bounced to 0.04 a few
days ago! I bet 0.045 will be hit again within this week. Buy ASAP!
Former Executive of Massachusetts Public Company Sentenced to Three Years for Lying and Obstructing Justice in an SEC Action
Litigation Release No. 21238 / October 6, 2009
Former Executive of Massachusetts Public Company Sentenced to Three Years for Lying and Obstructing Justice in an SEC Action
United States of America v. Howard P. Richman, Criminal Action No. 08-10282-MLW (D. Mass.)
Securities and Exchange Commission v. Biopure Corporation et al., Civil Action No. 05-11853-PBS (D. Mass.)
The Commission announced today that on October 5, 2009 Howard Richman, the former head of regulatory affairs of Biopure Corporation was sentenced to three years incarceration, three years of supervised release, a $50,000 fine, and a $100 mandatory special assessment. Richman, who was a defendant in a previously-filed Commission enforcement action, was indicted on September 24, 2008 by a grand jury convened by the United States Attorney for the District of Massachusetts. He pleaded guilty on March 11, 2009 for among other things lying and obstructing justice in an SEC action against him.
According to the Indictment, from October 26, 2006 through July 17, 2007, Richman represented to a federal judge that he was terminally ill with colon cancer and could not participate in an ongoing civil case that was brought against him by the Commission. The Indictment alleged that in reality, Richman did not have cancer. Rather, according to the Indictment, he falsely claimed to be terminally ill in order to avoid discovery and a scheduled trial in the SEC's case against him and to obtain a favorable settlement. The Indictment alleged that, to perpetuate his lie, Richman provided the Court with false affidavits and fabricated letters from a physician.
Previously, in September 2005, the Commission filed an enforcement action against Biopure, Richman and three other executives alleging that beginning in April 2003, Biopure received negative information from the FDA regarding its efforts to obtain FDA approval of its synthetic blood product Hemopure but failed to disclose the information, or falsely described it as positive developments in its filings with the Commission.
After Richman's lie was revealed, the Commission reached a settlement of its case with him, and the Court entered a final judgment by consent against Richman on August 6, 2008 permanently enjoining Richman from violating the antifraud and other provisions of the federal securities laws, permanently barring Richman from serving as an officer or director of any public company and ordering him to pay a $150,000 civil penalty. As a condition of his supervised release, Richman must enter into a payment plan with the Commission to pay the remainder of his $150,000 civil penalty. Biopure and three others previously settled SEC charges.
For further information, see Litigation Release No. 20947 (March 12, 2009), Litigation Release No. 20744 (September 25, 2008), Litigation Release No. 20672 (August 7, 2008)( SEC Settles Civil Injunctive Action with Former Executive of Massachusetts Public Company), Litigation Release No. 20010 (February 21, 2007)(SEC Settles Civil Injunctive Action Against Former CEO of Biopure Corporation), Litigation Release No. 19825 (September 12, 2006) (SEC Settles Civil Injunctive Action Against Biopure Corporation and Its General Counsel), Litigation Release No. 19651 (April 11, 2006) (SEC Settles with Former Biopure Executive) and Litigation Release No. 19376 (September 14, 2005) (Biopure and Others Charged by the Commission).
http://www.sec.gov/litigation/litreleases/2009/lr21238.htm
Who are those very stupid sellers who had sold tens of thousands of
shares at 0.031? Why? We already built up the rock support at 0.027
even the 52-week low is 0.025. Also BPURQ already rose to 0.04 from
0.027. Why the stupid sellers sold the shares at 0.027? I bet it is
the very sick MM's or shorter's manipulation! 0.045 is coming soon.
I am glad to own over 1M damn cheap shares at the cost about 0.029.
BPURQ is already bottomed out at 0.025 and will jump to .045 again!
I am ready to sell my shares at 0.04 ~ 0.045 to make big profit...
The pos scam seems bottomed out at 0.025 because 0.027 provided the
strong support even over 4M shares dumped at 0.025 ~ 0.03 so far. I
am glad to own over 1M damn cheap shares below 0.03. Do not sell at
the bid and please buy at the asking price only!
"Sell" confirmed by AmericanBull. We should see the pos scam drop to 0.025 ~ 0.027 today. Sell at the bid ASAP before that happens...
As I predicted the pos scam is heading onto the bottom 0.025. Sell!
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
347
|
Created
|
10/02/00
|
Type
|
Free
|
Moderators |
Outstanding Shares: 39,709,015 Shares.
Authorized Shares: 200,000,000 Shares.
Number Of Shareholders: 870.
Company Status: In CH11 process, no liquidation value.
Important Websites
Home Page: http://www.biopure.com/
Investor Kit: http://www.biopure.com/corporate/reports/bpur_ekit.zip
Corporate Contact
Biopure Corporation
11 Hurley Street
Cambridge, MA 02141
Phone 617-234-6500
Fax 617-234-6505
About Biopure Corporation (Nasdaq: BPUR)
Biopure Corporation develops, manufactures and markets oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. Using our patented and proprietary technology, we have developed and manufacture two products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)] for human use, and Oxyglobin® (HBOC-301) [hemoglobin glutamer - 200 (bovine)] for veterinary use. Hemopure is being sold in South Africa for the treatment of adult surgical patients who are acutely anemic and for eliminating, reducing or delaying the need for allogenic red blood cell transfusion in these patients. A marketing authorization application for Hemopure is pending in the United Kingdom, also for a surgery indication.
We have been developing Hemopure for the treatment of patients with cardiovascular ischemia and supporting the U.S. Navy's government-funded development of the product for out-of-hospital treatment of trauma patients in hemorrhagic shock. To exploit the body of preclinical and clinical information we have involving anemia, we are now beginning development for use of Hemopure in anemic cancer patients and end-of-life patients.
Oxyglobin, our veterinary product for the treatment of anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration (FDA) and the European Commission. We have sold approximately 200,000 units of Oxyglobin.
We are headquartered and operate a cGMP manufacturing facility in Cambridge, Massachusetts.
Products
Oxygen Bridge
The purpose of intravenous oxygen-delivery support is to help stabilize the patient and prevent tissue damage or organ dysfunction associated with oxygen deprivation. When Hemopure or Oxyglobin is infused into the bloodstream, its chemically stabilized hemoglobin molecules both carry oxygen in the plasma (the fluid part of blood) and facilitate the release of oxygen from red blood cells, thereby increasing diffusion of oxygen to tissues. If necessary, this effect can be extended over time by repeat dosing to provide a continuous Oxygen Bridge until anemic or ischemic patients receive other appropriate therapy.
Hemopure South Africa
HBOC-201 [hemoglobin glutamer - 250 (bovine)]
Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)], is a first-in-class product for human use and approved in South Africa for the treatment of acutely anemic adult surgical patients. Its purpose is to eliminate, reduce or delay these patients' need for allogenic red blood cell transfusions.
Current list: http://www.biopure.com/technology_and_products.php
Biopure Corporation Management
Zafiris G. Zafirelis
Chairman, President and Chief Executive Officer
Zafiris G. Zafirelis has been President, Chief Executive Officer and a director of Biopure since June 2004. In January 2006 he was appointed Chairman of the Board. Before coming to Biopure, he was CEO and a director of MedQuest Product, Inc, Salt Lake City, UT, a pioneering developer of implantable ventricular assist devices. He previously served as CEO and a director of CardiacAssist, Inc., Pittsburgh, PA, and, for four years prior to Biopure's initial public offering, as Director of Product Applications at Biopure. He holds a graduate diploma in chemistry from the University of Rhodesia and an M.B.A. from the University of Southern California.
David A. Butler
Interim Chief Financial Officer
Mr. Butler most recently served as Vice President, Finance and Administration at the Millard Group, Inc., a services & consulting company. Prior to that position, he served as Vice President, Finance, Chief Financial Officer and Treasurer at Circe Biomedical, Inc., a development-stage medical device manufacturer, formerly in Lexington, Mass.
Jane Kober
Senior Vice President, General Counsel and Secretary
Jane Kober has been Senior Vice President, General Counsel and Secretary of Biopure since 1998. From June 1989 to April 1998, she was a partner in LeBoeuf, Lamb, Greene & MacRae, L.L.P. Ms. Kober holds a J.D. degree from Case Western Reserve University, an M.A. degree from the University of Chicago and a B.A. in English from the Pennsylvania State University. She serves as a director of HTV Industries, Inc.
Geoffrey J. Filbey
Vice President, Engineering
Geoffrey J. Filbey joined Biopure in 1985 and has served as Vice President, Engineering since 1995. He previously worked at Stone & Webster Engineering Corporation for 14 years as a project manager and process engineer. Prior to Stone & Webster, he was a plant manager for eight years at Morganite Carbon Co. in London. Mr. Filbey holds a B.Sc. degree in engineering from the City University in London, England.
A. Gerson Greenburg
Vice President, Medical Affairs
A. Gerson Greenburg, M.D., Ph.D. joined Biopure as Vice President, Medical Affairs, in May 2006. He is a board-certified general surgeon and expert in oxygen therapeutics with over 40 years of experience in clinical care, quality systems, teaching and research. A professor emeritus of surgery at Brown University School of Medicine in Providence, R.I., Dr. Greenburg retired from The Miriam Hospital in April 2006 after serving as chief of clinical quality management since 2003 and as surgeon-in-chief from 1986 to 2005. In 2005, he received the hospital's Charles C.J. Carpenter Outstanding Physician of the Year Award. Previously, he was chief of general surgery and surgical intensive care at the Veterans Administration Medical Center in San Diego, Calif., and was a professor of surgery at the University of California, San Diego.
W. Richard Light
Vice President, Technology Development
W. Richard Light, Ph.D., rejoined Biopure as Vice President, Technology Development, in February 2005. During the previous year, Dr. Light was Vice President, Development, at Aeris Therapeutics in Woburn, Mass. He originally joined Biopure in 1990 and has held several positions, including Vice President, Process Technology; Director, Product Development; and Associate Director, Analytical and Protein Chemistry. Dr. Light previously served as a research biochemist and postdoctoral fellow at the Naval Research Laboratory in Washington, D.C. He holds a Ph.D. in biochemistry from Rice University, and has a B.S. in biology and a B.A. in chemistry from Washington & Lee University.
Virginia T. Rentko
Vice President, Preclinical Development
Virginia T. Rentko, V.M.D. is Vice President, Preclinical Development, at Biopure. She is board certified in internal medicine and is an adjunct clinical assistant professor in the Department of Clinical Sciences at Tufts University School of Veterinary Medicine. Dr. Rentko received her V.M.D. degree from the University of Pennsylvania and completed clinical training at the University of Pennsylvania and Tufts University. She obtained her M.S. degree in Zoology at the Ohio State University and her B.S. degree in Biology at Boston University. She is a diplomate of the American College of Veterinary Internal Medicine, and is an active member of the Association of Veterinary Hematology and Transfusion Medicine and the American Veterinary Medical Association.
Barry L. Scott
Vice President, Business Development
Barry L. Scott has been Vice President, Business Development, since September 2003. He joined the company in June 2002 as Vice President, International Business Development. From 1998 until 2002 Mr. Scott worked for Bristol-Myers Squibb Company, most recently as Vice President, International Business Development, Europe. From 1996 until 1998 he was the general manager of Bristol-Myers Squibb, Ltd., South Africa. He also held several positions, including Director of Marketing and Sales, during his 20 years at Merck Sharp and Dhome, the South Africa subsidiary of Merck & Co. Mr. Scott holds the Diploma in Education from the University of Rhodesia and the Diploma in Marketing Management from the Institute of Marketing Management, South Africa.
Filings and Other Information
http://sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000815508&owner=include&count=40
News
http://investor.biopure.com/phoenix.zhtml?c=114417&p=irol-news&nyo=0
Chart and Stock Information
Share Structure
O/S: 33,918,000
Ref: http://investor.biopure.com/phoenix.zhtml?c=114417&p=IROL-secToc&TOC=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvY29udGVudHMueG1sP2lwYWdlPTU1MzkzMjYmcmVwbz10ZW5r
American Stock Transfer & Trust Co.
Shareholder Services
59 Maiden Lane, Plaza Level
New York, NY 10038
Phone: 800-937-5449
Fax: 718-236-2641
Charts
_______________________________________
Updated 16 MAY 2008 by Soapy Bubbles
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |